{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:21:31Z","timestamp":1778019691094,"version":"3.51.4"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.1001\/jamaophthalmol.2022.0030","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T16:33:15Z","timestamp":1646325195000},"page":"337","source":"Crossref","is-referenced-by-count":15,"title":["Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants"],"prefix":"10.1001","volume":"140","author":[{"name":"Writing Committee for the Pediatric Eye Disease Investigator Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Elizabeth","family":"Hartnett","sequence":"additional","affiliation":[{"name":"John A. Moran Eye Center, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Indiana University, Indianapolis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevano W.","family":"Dean","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuokai","family":"Li","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charline S.","family":"Boente","sequence":"additional","affiliation":[{"name":"Indiana University, Indianapolis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eniolami O.","family":"Dosunmu","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center, Abrahamson Pediatric Eye Institute, Cincinnati, Ohio"},{"name":"Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon F.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Duke Eye Center, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard P.","family":"Golden","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingkun","family":"Kong","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Science Center, Lubbock"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Grace","family":"Prakalapakorn","sequence":"additional","affiliation":[{"name":"Duke Eye Center, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael X.","family":"Repka","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois E.","family":"Smith","sequence":"additional","affiliation":[{"name":"Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[{"name":"John A. Moran Eye Center, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond T.","family":"Kraker","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan A.","family":"Cotter","sequence":"additional","affiliation":[{"name":"Southern California College of Optometry at Marshall B. Ketchum University, Fullerton"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Science, University of Arizona, Tucson"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"3","key":"eoi220001r1","first-page":"227","article-title":"Childhood blindness in the context of VISION 2020\u2014the right to sight.","volume":"79","author":"Gilbert","year":"2001","journal-title":"Bull World Health Organ"},{"issue":"12","key":"eoi220001r2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial.","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"eoi220001r3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"eoi220001r4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"eoi220001r5","first-page":"2027","article-title":"Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity.","volume":"9","author":"Ar\u00e1mbulo","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"eoi220001r6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"eoi220001r7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment.","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"issue":"5","key":"eoi220001r8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II.","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"eoi220001r9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity.","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"issue":"11","key":"eoi220001r10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"eoi220001r11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity.","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi220001r12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study.","volume":"37","author":"Lorenz","year":"2017","journal-title":"Retina"},{"issue":"6","key":"eoi220001r13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study.","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi220001r14","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41598-018-20278-4","article-title":"Targeted knockdown of overexpressed VEGFA or VEGF164 in M\u00fcller cells maintains retinal function by triggering different signaling mechanisms.","volume":"8","author":"Becker","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"eoi220001r15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi220001r16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"eoi220001r17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"eoi220001r20","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International Classification of Retinopathy of Prematurity, third edition.","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi220001r21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi220001r22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis.","volume":"4","author":"Haigh","year":"2008","journal-title":"Organogenesis"},{"issue":"4","key":"eoi220001r23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity.","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"eoi220001r24","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment.","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"3","key":"eoi220001r25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1167\/iovs.13-11625","article-title":"Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity.","volume":"54","author":"McCloskey","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi220001r26","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bjo.2008.141481","article-title":"Anti-vascular endothelial growth factor and retinopathy of prematurity.","volume":"92","author":"Sears","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"1-1","key":"eoi220001r27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/pr.2015.181","article-title":"Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity.","volume":"79","author":"Hellgren","year":"2016","journal-title":"Pediatr Res"},{"issue":"8","key":"eoi220001r28","first-page":"3147","article-title":"Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?","volume":"6","author":"George","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"8","key":"eoi220001r29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial.","volume":"9","author":"Fidler","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"eoi220001r30","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"6","key":"eoi220001r31","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity.","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"eoi220001r18","year":"2019"},{"key":"eoi220001r19","unstructured":"Jaeb Center for Health Research. PEDIG home page. Accessed August 23, 2021. https:\/\/public.jaeb.org\/pedig"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2789630\/jamaophthalmology_hartnett_2022_oi_220001_1649949516.64409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T15:16:54Z","timestamp":1650554214000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2789630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.0030","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}